Brief: 2Seventy Bio, Bristol Myers Squibb Announced FDA Approval For Use Of Suspension Lentiviral Vector For Manufacturing Of Abecma

2Seventy Bio

09/04/2024 12:30

April 9 (Reuters) - Bristol-Myers Squibb Co  BMY.N :
    * 2SEVENTY BIO INC - CO, BRISTOL MYERS SQUIBB ANNOUNCED THAT
FDA
APPROVED USE OF SUSPENSION LENTIVIRAL VECTOR FOR MANUFACTURING
OF ABECMA
    * 2SEVENTY BIO INC SAYS ON APRIL 5, CO RECEIVES NOTICE FROM
ENGINE
CAPITAL LP THAT IT WITHDREW ITS TWO NOMINEES TO CO'S BOARD - SEC
FILING

Source text for Eikon:  ID:n0001860782-24-000057 
Further company coverage:  BMY.N 

 ((Reuters.Briefs@thomsonreuters.com;))